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Abstract
Introduction: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a
novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these
receptors in primary pancreatic cancer samples has not been sufficiently investigated and no study has yet addressed the
issue of their prognostic significance in this tumor entity.
Aims and Methods: Applying tissue microarray (TMA) analysis, we performed an immunohistochemical assessment of
TRAIL-receptors in surgical samples from 84 consecutive patients affected by pancreatic adenocarcinoma and in 26
additional selected specimens from patients with no lymph nodes metastasis at the time of surgery. The prognostic
significance of membrane staining and staining intensity for TRAIL-receptors was evaluated.
Results: The fraction of pancreatic cancer samples with positive membrane staining for TRAIL-R1 and TRAIL-R2 was lower
than that of cells from surrounding non-tumor tissues (TRAIL-R1: p,0.001, TRAIL-R2: p = 0.006). In addition, subgroup
analyses showed that loss of membrane staining for TRAIL-R2 was associated with poorer prognosis in patients without
nodal metastases (multivariate Cox regression analysis, Hazard Ratio: 0.44 [95% confidence interval: 0.2220.87]; p = 0.019).
In contrast, analysis of decoy receptors TRAIL-R3 and -R4 in tumor samples showed an exclusively cytoplasmatic staining
pattern and no prognostic relevance.
Conclusion: This is a first report on the prognostic significance of TRAIL-receptors expression in pancreatic cancer showing
that TRAIL-R2 might represent a prognostic marker for patients with early stage disease. In addition, our data suggest that
loss of membrane-bound TRAIL-receptors could represent a molecular mechanism for therapeutic failure upon
administration of TRAIL-receptors-targeting antibodies in pancreatic cancer. This hypothesis should be evaluated in future
clinical trials.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
death in the industrialized countries with an overall five-year
survival averaging less than 5% and a median survival of about six
months [1]. Its aggressive biology, the lack of early symptoms and
the absence of reliable screening methods are responsible for the
advanced stage of this disease at the time of diagnosis. Neither
recent improvements in surgical procedures nor radio- or
chemotherapeutic regimens have yet led to a significant improve-
ment in patient survival. Consequently, significant effort is being
devoted to the development of novel and rational therapeutic
approaches that target the critical molecular features in this tumor
entity.
In recent years, the administration of agonistic antibodies
targeting the receptors for TNF-related apoptosis-inducing ligand
(TRAIL) has pre-clinically been demonstrated to represent a
promising therapeutic avenue, which is at this time undergoing
clinical investigation in numerous tumor entities including
pancreatic cancer [2–6]. TRAIL plays a role in a wide variety
of biological processes including the induction of apoptosis in
cancer cells upon binding to its receptors on the outer cell
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membrane. Of particular importance, it has been shown that
apoptosis triggered by TRAIL plays a critical role for tumor
surveillance by causing the immune-mediated clearance of
metastatic cells; TRAIL-knockout mice exhibit enhanced metas-
tases formation [7], loss of TRAIL receptor-expression is
associated with poor prognosis and tumor recurrence in patients
suffering from a variety of different tumor types [8], and
expression of the TRAIL-binding soluble decoy receptor osteo-
protegerin correlates with tumor stage and metastasis formation in
colorectal cancer patients [9], establishing a strong rationale for
the development of TRAIL-receptors-targeting compounds as
therapeutic anticancer strategy.
In spite of the growing interest for TRAIL-receptors as
therapeutic target in cancer, studies on the expression, spatial
distribution and relevance of TRAIL-receptors as prognostic
markers in pancreatic cancer are still lacking. Specifically, little is
known about the expression and functional availability of distinct
TRAIL-receptors on the surface of pancreatic cancer cells, despite
the availability of agonistic antibodies targeting either TRAIL-R1
or TRAIL-R2 currently used in clinical trials. By applying tissue-
microarray analyses to evaluate TRAIL-R1 and TRAIL-R2
expression status in a large cohort of surgical specimens of
pancreatic adenocarcinoma, we found that loss of membrane
staining for these receptors is a common feature of pancreatic
cancer. Thus, failure to achieve therapeutic effects using TRAIL-
receptors targeting compounds in clinical trials might be due to the
lack of selection of the patients with tumors expressing membrane-
bound TRAIL-receptors. In addition, loss of membrane-bound
TRAIL-R2 in tumors from patients with no nodal metastases at
the time of diagnosis is associated with a poor prognosis in our
cohort, potentially establishing TRAIL-R2 as a prognostic marker
in specific of pancreatic cancer patients.
Patients and Methods
Ethics Statement
According to the guidelines of our University, immunohisto-
chemical staining of archived tissue samples may be performed
provided that anonymity is granted. Therefore, approval of this
study was waived by the ethical committee of the University of
Munich and no written consent was required.
Case Identification, Selection and Patients’ Follow-up
Patients with histologically confirmed pancreatic ductal adeno-
carcinoma, who underwent surgery for pancreatic cancer
(Whipple procedure, distal pancreatectomy, or total pancreatec-
tomy) at the Department of Surgery at the Ludwig-Maximilians-
University of Munich between January 31st, 2003 and June 14th,
2007, were considered for tissue microarray (TMA) construction.
As a second step, this patients’ collective was successively
broadened by the inclusion of additional 26 consecutive patients
with no nodal metastasis undergoing surgery until October 7th
2011 to enable the specific evaluation of the prognostic
significance of TRAIL-receptors in determining the risk of
recurrence after radical resection. All clinicopathologic data were
collected from the database of the Munich Cancer Registry and
the original patients’ charts.
In our study, the majority of patients (98 of 110, 89%)
received adjuvant therapy including gemcitabine, either as
monotherapy (n= 35) or in combination with radiotherapy
(n = 50) and/or other agents, including 5-fluorouracil, oxaliplatin
and cisplatin.
TMA Construction
Paraffin-embedded archived tissue material of tumor and
surrounding normal pancreatic tissue was used for TMA
construction. TMAs were prepared as published before [10]. In
brief, the area of interest to be sampled was identified and marked
on hematoxylin-eosin stained tissue slides. From the corresponding
paraffin block (donor block), tissue core biopsies (each 0.6 mm in
diameter) were taken out and then arrayed in a recipient TMA
block using a manual arrayer (Beecher Instruments, Sun Prairie,
WI). Each case was represented by three core biopsies from
different parts of the pancreatic carcinoma and two core biopsies
from corresponding normal pancreatic tissue to exclude artefacts
due to heterogeneous antigen expression and to allow comparisons
between normal exocrine pancreatic tissue and tumor tissue.
Immunohistochemistry was performed on 2 mm sections of the
TMA.
Immunohistochemical Staining
5 mm sections of TMA blocks were used for immunohisto-
chemical staining. Anti-TRAIL R1 polyclonal goat antibody
(Santa Cruz Biotechnology Inc., Heidelberg, Germany) and Anti-
TRAIL R2 polyclonal rabbit antibody (Calbiochem, CA, USA)
were applied as primary antibodies. Both antibodies were
previously validated for immunohistochemistry of TRAIL-recep-
tors in our laboratory [8]. For antigen retrieval, sections were pre-
treated by boiling in a microwave oven 2 times at 15 min at
750 W in Target Retrieval Solution (Dako, Hamburg, Germany).
Endogenous peroxidase was blocked by incubation in 7.5%
hydrogen peroxide for 10 minutes. Vectastain ABC-Kit Elite
Universal (Vector Laboratories, CA, USA) kit was taken for
antibody detection and AEC (Zytomed Systems) was used as a
chromogen. Slides were counterstained with hematoxylin (Vector).
For evaluation of decoy receptors TRAIL-R3 and TRAIL-R4 the
following antibodies were used: TRAIL-R3 polyclonal rabbit
antibody (Gene Tex, CA, USA) and TRAIL-R4 monoclonal
mouse antibody (US Biology, MA, USA). Positive staining for
TRAIL-receptors was first categorized according to its cellular
distribution and regardless of the intensity of the signal as follows:
positive staining in cytoplasm only, positive staining on cell
membranes only, and positive staining in both cell membrane and
cytoplasm. For statistical analyses, tumors exhibiting TRAIL-
receptors staining on cell membranes (‘‘membrane staining’’
group) were compared to tumors without TRAIL-receptors
staining or with TRAIL-receptors expression confined to cyto-
plasm only (‘‘no membrane staining’’ group) according to the
rationale that TRAIL-receptors are functionally active only if
situated on the surface of cell membranes [11]. Additionally, we
conducted a semi-quantitative analysis of pancreatic cancer
samples by assigning a score depending on the overall TRAIL-
receptors staining intensity (0: no staining, 1+ low staining
intensity, 2+ high staining intensity).
Statistics
Overall survival was defined as the interval from the date of
surgery to death or to the most recent contact (for censored events)
as of September 1st, 2012. Categorical data were compared by
Chi-Square or Fisher’s exact tests, continuous data were compared
by the t-test. Overall median survival times were estimated using
the Kaplan-Meier method. The log-rank test was used to test for
homogeneity of the survival curves. Univariate and multivariate
Cox proportional hazards models were used to assess the effects of
variables on overall survival. Follow-up maturity was validated by
assessment of follow-up curves for the living patients to ensure
comparable follow-up times of survival curves between the
TRAIL-Receptors in Pancreatic Cancer
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e56760
respective independent groups [24]. Statistical analyses were
performed using Statistical Package for Sciences software (SPSS
Inc., Chicago, IL, USA). Two-sided P values of less than 0.05 were
considered statistically significant.
Results
Patient Selection and and Clinicopathological Features
84 consecutive patients with histologically confirmed pancre-
atic ductal adenocarcinoma, who underwent surgery for
pancreatic cancer at the Department of Surgery at the
Ludwig-Maximilians-University of Munich between January
31st, 2003 and June 14th, 2007, were identified. Since the
expression of TRAIL-receptors has been shown to be affected
by the administration of chemotherapy and radiotherapy [12–
14], patients who received neoadjuvant chemotherapy or
neoadjuvant irradiation were not considered for statistical
analyses. Furthermore, patients who died as a result of
immediate postoperative complications and patients for whom
no follow up was available were excluded.
Where histological data were missing (TRAIL-R1:5 normal
tissue samples; TRAIL-R2:9 normal tissue samples and 5 tumor
tissue samples) only matching samples were considered for the
comparison of categorical data between normal and tumor
tissues. All patients selected for this study (n= 84) had a
complete follow-up either until death (n = 72) or until their most
recent contact (n = 12) on September 1st, 2012. The shortest
follow-up after surgery for patients still alive as of September 1st
2012 was 62.6 months. The longest follow-up for patients still
alive was 106.5 months. The median patient age at the time of
surgery was 65 years (range 32–81). A summary of the
clinicopathologic features of this patients’ cohort is shown in
table 1. As a second step, the patients’ collective was extended
by the addition of 26 consecutive patients with no nodal
metastasis at the time of surgical intervention who were treated
in the subsequent three years’ time period until October 7th
2011. A summary of the clincopathological features of No
patients’ subgroup is provided in table S1.
Immunohistochemical Staining for TRAIL Receptors 1
and 2 in Pancreatic Cancer and Matched Surrounding
Tissues
To assess TRAIL-receptors status in pancreatic cancer
samples and matched surrounding tissue, we first conducted a
semi-quantitative analysis of TRAIL-receptors-1 and -2 staining
intensity regardless of their cellular distribution applying an
intensity staining score ranging from 0 to 2.
Positive staining for TRAIL-R1 was found in 77% of tumor
samples and 89% of matched surrounding tissue. Instead, positive
staining for TRAIL-R2 was found in 99% of both tumor samples
and matched surrounding pancreatic tissue (table S2). However,
when assessing staining intensity for TRAIL-R2, this receptor
appeared to have a lower staining in tumor tissue samples
compared to matched non-tumor tissue, with the majority of non-
tumor samples showing high intensity-staining (high intensity-
staining in non-tumor tissue samples = 71% vs. 48% of tumor
tissue samples - McNemar-Bowker test: p = 0.021, table S2). The
higher percentage of tumor samples showing a negative staining
for TRAIL-R1 and the overall higher intensity staining score for
TRAIL-R2 in non-tumor samples indicates a loss of TRAIL-
receptors expression in tumor samples vs. matched non tumor
tissue samples.
Next, we analyzed the spatial intracellular distribution of
TRAIL receptors by considering the fraction of cells in cancer
and surrounding non-tumor tissues according to whether the
immunohistochemical analysis showed cytoplasmatic staining,
membranous staining or both. Representative figures of different
staining patterns of TRAIL-R2 are shown (fig. 1). Importantly,
TRAIL-R1 showed positive membrane staining in 84% of normal
surrounding pancreatic tissue samples but only in 44% of
pancreatic cancer samples, while TRAIL-R2 showed positive
membrane staining in 99% of normal and in 81% of pancreatic
cancer samples (fig. 2). Thus, the fraction of samples exhibiting
membrane staining was significantly lower in cancer than in
matched surrounding normal tissues (McNemar test: TRAIL-R1:
p,0.001; TRAIL-R2: p= 0.006).
Table 1. Summary of clinicopathologic features.
Feature Patient count
n %
Age, median (y)
#65 39 46
.65 45 54
Gender
Female 43 51
Male 41 49
Tumor differentiation
Well 1 1
Moderate 27 32
Poor 56 67
Tumor pathologic stage
T1 2 2
T2 9 11
T3 70 83
T4 3 4
Lymph node status
No 36 43
N1 48 57
Metastasis status
M0 73 87
M1 11 13
Tumor size, median (cm)
,3.5 cm 33 39
$3.5 cm 51 61
Margin status
Negative 42 50
Positive 42 50
Postoperative radiotherapy
No 34 40
Yes 50 60
Postoperative chemotherapy
No 12 14
Yes 72 86
doi:10.1371/journal.pone.0056760.t001
TRAIL-Receptors in Pancreatic Cancer
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Correlation of TRAIL-receptors Staining with
Clinicopathological Features of Tumor Tissues and
Surrounding Normal Pancreatic Tissue
To assess whether TRAIL-receptors staining in tumor samples
and matched non-tumor tissue samples was associated with
specific clinicopathological features, membrane staining of
TRAIL-receptors was correlated to clinical and pathological
features of tumors including grading, size and staging of tumors,
the presence or absence of tumor-free margins after surgical
resection and the post-interventional application of radio- and/or
chemotherapy. However, no significant correlations were found
between TRAIL-receptors staining on cell membranes in pancre-
atic cancer (table 2) or surrounding cells (not shown) and any of the
above features. Similarly, analyses correlating these parameters
with the staining intensity of TRAIL-receptors regardless of their
cellular distribution did not show any significant association (data
not shown).
Prognostic Significance of TRAIL-receptors Staining in
Patients Undergoing Surgery
As expected, Kaplan-Meier and univariate Cox regression
analyses demonstrated lymph nodes (No vs. N1), metastases (M0
vs. M1) and tumor size (median, ,3.5 cm vs. $3.5 cm) to
represent significant determinants of overall survival (figure S1,
table 3). In contrast, no correlations were found between overall
survival and membranous expression of TRAIL-R1 or TRAIL-
R2, respectively (Kaplan-Meier log rank test: TRAIL-R1:
p = 0.842, TRAIL-R2: p = 0.176, fig. 3A and 3B). Similarly,
analyses stratifying patients according to the semi-quantitative
assessment of TRAIL-receptors staining intensity regardless of the
cellular distribution (scoring ranging from 0 to 2+) did not yield
significant survival differences (Kaplan-Meier long rank test:
TRAIL-R1: p= 0.279; TRAIL-R2: p= 0.339– data not shown).
However, subgroup analyses revealed that patients without nodal
metastasis at the time of surgery had a better prognosis if
membrane-bound staining for TRAIL-R2 was positive (HR: 0.30
[0.12–0.76]; p = 0.011– data not shown), whereas no significant
associations were found for membrane-bound TRAIL-R1 expres-
sion and survival in this subgroup (HR: 1.21 [0.58–2.54],
p = 0.608). In support of the data obtained for TRAIL-R2,
multivariate analysis including variables associated with overall
survival in the univariate analyses with p,0.2, indicated that
TRAIL-R2 membrane staining was an independent factor of
survival in this subgroup (calculated HR: 0.36 [0.14–0.91],
p = 0.031).
Figure 1. Representative micrographs of TRAIL-R2 staining in normal pancreatic tissue and pancreatic cancer cells showing: typical
positive staining of TRAIL-R2 in normal tissue (A), negative staining of TRAIL-R2 in tumor tissue (B) and intracellular spatial
distribution of TRAIL-R2 in tumor tissue with prevalent staining of the cell membranes (C), cytoplasm (D) or both (E). Scale bars
represent 50 mm.
doi:10.1371/journal.pone.0056760.g001
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To substantiate our results on the No population, we
subsequently extended the size of this subgroup to include 26
additional No patients who underwent surgery for pancreatic
cancer in the three years period following that of the previous
TMA collective. Analysis of survival in this extended subset of
altogether 58 patients confirmed that only membrane staining of
TRAIL-R2 was associated with a better survival (univariate
analysis: TRAIL-R1: HR 1.22 [0.66–2.25], p= 0.514; TRAIL-R2
(HR 0.45 [0.22–0.88], p= 0.019– figure 3 C, D). Multivariate
analysis, including variables associated with overall survival in the
univariate analyses with p,0.2, (i.e. gender, grading, median
tumor size, and TRAIL-R2 membrane staining) confirmed the
independent prognostic significance of membrane staining for
TRAIL-R2 in this subgroup (adjusted for all: HR 0.47 [0.23–
0.96], p = 0.041; backward elimination: HR 0.44 [0.2220.87],
p = 0.019).
Staining and Cellular Distribution of Decoy Receptors
TRAIL-R3 and TRAIL-R4 in Pancreatic Cancer Cells
Decoy receptors for TRAIL have shown to play a role in the
pathogenesis of tumors as revealed by reports published previously
by our and other laboratories [9,15,16], but presently no
information on the prognostic significance of decoy receptors for
TRAIL in pancreatic cancer is available. To investigate the
potential role of these receptors in antagonizing the effects of
TRAIL-R1 and -R2, additional analyses were performed and
TRAIL-R3 and TRAIL-R4 staining in tumor samples of our
patients’ collective assessed. In agreement with the previous
reports, our analyses showed positive TRAIL-R3 and TRAIL-R4
staining in 52% and 69% of tumor samples respectively, and a
high-intensity staining in 10% and 16% of cases respectively.
However, the staining of these receptors was restricted exclusively
to the cytoplasm and had no prognostic significance in our cohort
(TRAIL-R3: HR 0.95 [0.59–1.51], p= 0.840; TRAIL-R4: HR
1.06 [0.64–1.76], p = 0.806).
Discussion
Targeted Therapies and TRAIL-signaling in Pancreatic
Cancer
The recognition of the role played by TRAIL-mediated
apoptosis in the process of immune surveillance counteracting
tumor formation has led to the development and clinical
employment of TRAIL-receptors targeting compounds as anti-
Figure 2. TRAIL-R1 and TRAIL-R2 membrane staining in pancreatic cancer tissue and in surrounding pancreatic cells. Percentage of
samples showing no staining (none), cytoplasmatic staining (cytoplasm only), membrane staining (membrane only) or both (m+c).
doi:10.1371/journal.pone.0056760.g002
TRAIL-Receptors in Pancreatic Cancer
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cancer therapy; at this time, monoclonal antibodies targeting
TRAIL-R1 (e.g. mapatumumab [17]) or TRAIL-R2 (e.g.
tigatuzumab [18]), or recombinant forms of human TRAIL
[19], are undergoing extensive clinical investigation. Although the
mere expression of receptors for TRAIL does not represent the
only determinant of response to the apoptotic effect of TRAIL
[20], it is likely that the efficacy of these compounds will act in a
TRAIL-receptor expression-dependent fashion in individual
tumors. Surprisingly however, while the frequent loss of TRAIL-
receptors reported for several tumor entities could impede the
clinical efficacy of these compounds [8,21–23], no large systematic
report on the spatial cellular distribution and prognostic meaning
of TRAIL-receptors in pancreatic cancer is yet available (reviewed
in [3]). Furthermore, while early phase clinical trials with TRAIL-
receptors-targeting compounds or antibodies have just recently
been initiated in patients with pancreatic cancer, the results from
clinical trials with TRAIL-receptors-targeting compounds in
colorectal and non-small-cell lung cancer have shown disappoint-
ing results [17,19], prompting a timely clarification of the role of
these agents in the therapy of solid tumors.
Staining and Intracellular Localization of TRAIL-receptors
in Tumors Versus Surrounding Pancreatic Tissues
Considering the overall staining of tumor and matched normal
pancreatic samples, we found that almost all samples stained
positive for TRAIL-R2; instead, TRAIL-R1 stained negative in
23% of tumor samples and in 11% of matched normal pancreatic
samples. The loss of TRAIL-R1 staining in tumor cells in
comparison to co-stained surrounding non-tumor tissues from the
same patient is in agreement with previous reports on other tumor
entities [23,24] and with in vitro evidence showing that loss of
TRAIL-receptors in pancreatic cancer cell lines contributes to a
decreased sensitivity towards TRAIL-induced apoptosis [25].
However, the only other published study on the prevalence of
TRAIL-receptors in pancreatic cancer demonstrated upregulation
of TRAIL-R1 in 38 pancreatic cancer samples as compared to 31
Table 2. Associations between membrane staining of TRAIL-receptors and clinicopathologic features.
Feature TRAIL-R1 TRAIL-R2
Membrane Staining P Membrane Staining P
Negative, n (%) Positive, n (%) Negative, n (%) Positive, n (%)
Age, median (y) 0.337 0.556
#65 24 (28.6) 15 (17.8) 6 (7.6) 31 (39.2)
.65 23 (27.4) 22 (26.2) 9 (11.4) 33 (41.8)
Gender 0.365 0.110
Female 22 (26.2) 21 (25.0) 5 (6.3) 36 (45.6)
Male 25 (29.8) 16 (19.0) 10 (12.7) 28 (35.4)
Tumor differentiation 0.876 0.362
Well and moderate 16 (19.0) 12 (14.3) 3 (3.8) 23 (29.1)
Poor 31 (36.9) 25 (29.8) 12 (15.2) 41 (51.9)
Tumor pathologic stage 0.784 0.612
T1 and T2 7 (8.3) 4 (4.8) 2(2.4) 5 (6.3)
T3 and T4 40 (47.6) 33 (39.3) 13 (16.5) 59 (70.2)
Tumorsize, median (cm) 0.254 0.386
,3.5 21 (25.0) 12 (14.3) 4 (5.1) 26 (32.9)
$3.5 26 (30.9) 25 (29.8) 11 (13.9) 38 (48.1)
Lymph node status 0.409 0.261
No 22 (26.2) 14 (16.6) 8 (10.1) 24 (30.4)
N1 25 (29.8) 23 (27.4) 7 (8.9) 40 (50.6)
Metastasis status 0.102 1,000
M0 38 (45.2) 35 (41.7) 13 (16.5) 55 (69.6)
M1 9 (10.7) 2 (2.4) 2 (2.5) 9 (11.4)
Margin status 0.826 0.485
Negative 24 (28.6) 18 (21.4) 6 (7.6) 32 (40.5)
Positive 23 (27.4) 19 (22.6) 9 (11.4) 32 (40.5)
Postoperative radiotherapy 0.991 0.603
No 19 (22.6) 15 (17.8) 5 (6.3) 26 (32.9)
Yes 28 (33.3) 22 (26.2) 10 (12.7) 38 (48.1)
Postoperative chemotherapy 0.119 0.391
No 4 (4.8) 8 (9.5) 3 (3.8) 7 (8.9)
Yes 43 (51.2) 29 (34.5) 12 (15.2) 57 (72.1)
doi:10.1371/journal.pone.0056760.t002
TRAIL-Receptors in Pancreatic Cancer
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non-malignant pancreatic ductal tissue samples from control
patients [26]. Several explanations exist for the different results
obtained in this study versus our study, including a lower patient
number in the other cohort, the source and representativeness of
the samples (partly biopsies in the other study versus solely surgical
specimens in our study), and the inclusion (11 of 34 patients) versus
exclusion of patients having received neo-adjuvant therapy,
together with the fact that the expression of TRAIL-receptors is
increased by chemo2/or radiotherapy [27,28].
Most previous reports on TRAIL-receptors expression in
different tumor entities were based on semi-quantitative criteria
[22,26,29]; however, recent studies have shown that particularly
the sub-cellular localisation of TRAIL-receptors might influence
their function; specifically, while internalization of the pro-
apoptotic receptor CD95 plays a stimulatory role in the
transduction of apoptotic signalling, internalization of TRAIL-
receptors inhibits caspase activation [30]. We recently proposed
that TRAIL-receptors expression should be evaluated by analyz-
ing the fraction of membrane-bound TRAIL-receptors, based on
the rationale of assessing the fraction of TRAIL-receptors
effectively exposed to circulating TRAIL as supposedly predom-
inant prognostic determinant [8]. Accordingly, we considered not
only the staining intensity, but also the intracellular distribution of
staining, i.e. the fraction of tumors exhibiting TRAIL-receptors
staining on cell membranes in our study. We found that 56% of
tumor samples displayed no membrane staining for TRAIL-R1
and 19% for TRAIL-R2 with the extent of membrane staining
varying inversely with the cytoplasmatic staining, suggesting that
internalization of TRAIL-receptors could represent a mechanism
for the loss of functional TRAIL receptors as a distinctive feature
of pancreatic cancer cells, a hypothesis recently corroborated by
other studies in vitro [11,31].
Figure 3. Kaplan-Meier curves of overall survival in patients with resected pancreatic adenocarcinoma. Graphs show survival according
to TRAIL-R1 membrane staining (A), TRAIL-R2 membrane staining (B) and subgroup analysis of survival according to TRAIL-R1 (C) and TRAIL-R2 (D)
membrane staining in patients with no nodal metastasis at the time of surgery.
doi:10.1371/journal.pone.0056760.g003
TRAIL-Receptors in Pancreatic Cancer
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Prognostic Impact of TRAIL-receptors Expression in
Pancreatic Cancer
To assess whether loss of membrane-bound TRAIL-receptors
might have prognostic significance, we subsequently correlated
TRAIL-receptors staining with survival. Five-year survival of
patients harboring tumors exhibiting TRAIL-R1 or TRAIL-R2
did not significantly differ from that of other patients. Similar
results were obtained by stratifying patients according to TRAIL-
receptors intensity staining scores. However, membrane staining
for TRAIL-R2 was associated with a better prognosis in a
subgroup of patients without nodal metastases at the time of
Table 3. Univariate Analysis of overall survival in patients with resected pancreatic ductal adenocarcinoma.
Variables No. Survival* HR 95% CI P
Lower Upper
Age, median (y)
#65 39 19.4 1.00 0.685
.65 45 16.6 1.06 0.66 1.69
Gender
Female 43 13.1 1.00 0.192
Male 41 19.6 0.73 0.46 1.16
Tumor differentiation
Well to
Moderate
28 28.7 1.00 0.259
Poor 56 14.6 1.32 0.81 2.17
Tumor size, median (cm)
,3.5 33 28.4 1.00 0.002
$3.5 51 13.1 2.14 1.31 3.50
Lymph node status
No 36 28.1 1.00 0.015
N1 48 13.1 1.80 1.11 2.90
Metastasis status
M0 73 19.6 1.00 0.002
M1 11 10.2 2.83 1.45 5.54
Margin status
Negative 42 18.9 1.00 0.673
Positive 42 16.1 1.10 0.69 1.75
TRAIL-R1 membrane staining
Negative 47 14.9 1.00 0.842
Positive 37 18.9 1.05 0.65 1.67
TRAIL-R2 membrane staining
Negative 15 14.6 1.00 0.179
Positive 64 18.9 0.66 0.36 1.20
TRAIL-R3 expression
Negative 40 14.8 1.00 0.840
Positive 43 19.3 0.95 0.59 1.51
TRAIL-R4 expression
Negative 26 17.1 1.00 0.806
Positive 57 16.4 1.06 0.64 1.76
TRAIL-R1 membrane staining
in patients with No
Negative 22 28.6 1.00 0.608
Positive 14 21.1 1.21 0.58 2.54
TRAIL-R2 membrane staining
in patients with No
Negative 8 17.1 1.00 0.011
Positive 24 30.8 0.30 0.12 0.76
*Median survival time in months from date of surgery to death or to most recent contact.
doi:10.1371/journal.pone.0056760.t003
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surgery, which is consistent with recent evidence that the fraction
of membrane-bound receptors determines their functional status
[11,31] and plays a major prognostic role in patients with
hepatocellular carcinoma [8].
Although we found no specific correlation between TRAIL-
receptors expression and tumor stage in our cohort, the fact that
TRAIL-receptors expression was not associated with any patho-
logical parameter supports the hypothesis that, rather than
influencing tumor initiation, loss of TRAIL-receptors might affect
tumor progression at a later stage due to the selection of cell clones
resistant to circulating TRAIL and to immune-mediated mecha-
nisms controlling clearance of metastatic cells [32,33]. Thus, the
lack of correlation between TRAIL-receptors status and prognosis
in patients with metastatic disease at the time of surgery is likely
ascribable to other predominating metastasis-determining factors
outweighing the effects of TRAIL-receptors loss at later stages.
Recent reports have shown that apoptosis is preferentially
triggered in pancreatic cancer cells by TRAIL-R1 especially in
combination with XIAP inhibitors, whereas stimulation of
TRAIL-R2 requires cross-linking for efficient induction of
apoptosis [34]. These data suggest that TRAIL-R1 should be
the preferential target of TRAIL-R-targeting agents in pancreatic
cancer. Our data showing a lower prevalence of membrane
staining of TRAIL-R1 vs. TRAIL-R2 seem to confirm the fact
that loss of functional TRAIL-R1 represents an important step of
carcinogenesis. However, the prognostic relevance of TRAIL-R2
in patients with no metastasis at the time of surgery suggests that
this receptor might exert a physiological role as a tumor-
suppressor at this stage of tumor development.
In opposition to the positive prognostic significance of TRAIL-
R2, we found no correlation between TRAIL-R3 or TRAIL-R4
and survival. Decoy receptors for TRAIL have shown to play a
role in the pathogenesis of tumors as revealed by reports on the
detrimental prognostic effect of TRAIL-R3 expression in colorec-
tal cancer [15] or of TRAIL-R4 in breast cancer [16], and by our
previously published data on the role of the soluble decoy receptor
OPG in determining the resistance to apoptosis in colorectal
cancer patients [9]. Our finding that TRAIL-R3 and TRAIL-R4
staining in tumor samples is found exclusively in the cytoplasm is
in agreement with the previous finding that positive staining for
TRAIL-R1 and -R2, but negligible staining for TRAIL-R3 and -
R4 could be found on the surface of different pancreatic cancer
cell lines by FACS analysis [34]. Future studies will have to assess
whether the absence of membrane staining for TRAIL-R3 and -4
might reflect the lack of prognostic significance of these receptors
in pancreatic cancer in contrast to the tumor entities where a
negative correlation with survival was shown.
Clinical Consequences of TRAIL-receptors Loss in
Pancreatic Cancer Cells
A clinical consequence of the frequent functional loss of
TRAIL-receptors in pancreatic cancer may be represented by
the fact that many pancreatic tumors do not respond to the
administration of the specific agonistic antibodies targeting either
TRAIL-R1 such as Mapatumumab or TRAIL-R2 such as
Tigatuzumab [27]. Therefore, clinical trials based on the
administration of such agents might have to take the status of
the respective membrane staining into account.
The mechanisms by which TRAIL-receptors are lost in tumor
cells are not yet fully understood. Genetic loss or mutation of
TRAIL-receptors is a rare event in cancer cells, averaging 1% in
hepatocellular carcinoma [21,35], and being absent in pancreatic
cancer in large-scale comprehensive genetic analyses [36,37].
Furthermore, as several compounds [11,38–42] can increase
TRAIL-receptors expression or exposure on cell membranes,
epigenetic gene silencing and TRAIL-receptors internalization
indicate a potentially reversible mechanism for the loss of
functional TRAIL-receptors in cancer. Importantly, it has been
recently shown that silencing HuR augments TRAIL-R2 produc-
tion by enabling its translation, hereby enhancing TRAIL-
mediated apoptosis [43]. Thus, tumors displaying negative
membrane staining for TRAIL-receptors might be susceptible to
agents capable of increasing TRAIL-receptors expression, thereby
restoring the efficacy of endogenous TRAIL [44,45]. Also,
TRAIL-receptors agonistic antibodies might synergize to induce
apoptosis in combination with agents capable of increasing
TRAIL-receptors expression or overcome intracellular resistance
to TRAIL [3,12,43,45,46].
In conclusion, this pilot study shows that loss of membrane-
bound TRAIL-receptors could represent a molecular mechanism
for therapeutic failure upon administration of TRAIL-receptors-
targeting antibodies in pancreatic cancer. TRAIL-R2 might
represent a prognostic marker for patients with early stage disease.
Immunohistochemical analysis of prospectively collected tissues in
the context of current clinical trials using TRAIL-receptors
agonistic antibodies will provide definitive evidence on the
importance of these receptors and of their spatial distribution in
determining the prognosis of pancreatic cancer patients, and on
their relevance as a biomarker of response to these novel anti-
cancer compounds.
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